Skip to main content

Table 3 Estimated odds ratios of being a responder with daridorexant 50 mg versus placebo

From: Understanding daytime functioning in insomnia: responder and correlation analyses in patients treated with daridorexant

 

Daridorexant 50 mg vs. Placebo

Treatment OR (95% CI)

P-value

Week 1

1.6 (0.9, 2.7)

0.0923

Week 2

2.1 (1.3, 3.2)

0.0012

Week 3

2.7 (1.8, 4.1)

< 0.0001

Week 4

2.4 (1.6, 3.6)

< 0.0001

Week 5

2.0 (1.4, 2.8)

0.0002

Week 6

1.4 (1.0, 1.9)

0.0773

Week 7

1.6 (1.1, 2.2)

0.0141

Week 8

1.6 (1.1, 2.2)

0.0097

Week 9

1.3 (0.9, 1.9)

0.1078

Week 10

1.9 (1.4, 2.7)

0.0002

Week 11

1.6 (1.1, 2.2)

0.0072

Week 12

1.5 (1.1, 2.1)

0.0134

  1. CI confidence interval, OR odds ratio
  2. Odds ratios of a patient achieving ≥ 20–point decrease in IDSIQ total score from baseline at a given week with daridorexant 50 mg vs placebo. Regression analysis approach: Population-averaged model. Fitted fixed factors: Age group, week, treatment group, treatment group x week interaction. Results are estimates for treatment group x week interaction fixed effect